CN111323527A - 一种用复合二维液相色谱同时测定多种精神药物的方法 - Google Patents
一种用复合二维液相色谱同时测定多种精神药物的方法 Download PDFInfo
- Publication number
- CN111323527A CN111323527A CN201811523318.2A CN201811523318A CN111323527A CN 111323527 A CN111323527 A CN 111323527A CN 201811523318 A CN201811523318 A CN 201811523318A CN 111323527 A CN111323527 A CN 111323527A
- Authority
- CN
- China
- Prior art keywords
- column
- dimensional
- sample
- flow channel
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 229940001470 psychoactive drug Drugs 0.000 title claims abstract description 25
- 239000004089 psychotropic agent Substances 0.000 title claims abstract description 25
- 239000002131 composite material Substances 0.000 title claims abstract description 14
- 238000004780 2D liquid chromatography Methods 0.000 title claims description 7
- 238000004458 analytical method Methods 0.000 claims abstract description 37
- 239000000945 filler Substances 0.000 claims abstract description 32
- 238000000605 extraction Methods 0.000 claims abstract description 27
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 239000004005 microsphere Substances 0.000 claims abstract description 17
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 19
- 229960004688 venlafaxine Drugs 0.000 claims description 19
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 17
- 229960003036 amisulpride Drugs 0.000 claims description 17
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims description 16
- 229960001623 desvenlafaxine Drugs 0.000 claims description 15
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 13
- 229960004940 sulpiride Drugs 0.000 claims description 13
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 10
- ZRIUUUJAJJNDSS-UHFFFAOYSA-N ammonium phosphates Chemical compound [NH4+].[NH4+].[NH4+].[O-]P([O-])([O-])=O ZRIUUUJAJJNDSS-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000002699 waste material Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000004811 liquid chromatography Methods 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical group OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 230000010355 oscillation Effects 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 238000000926 separation method Methods 0.000 abstract description 5
- 239000012071 phase Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000006920 protein precipitation Effects 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- -1 desmethylvenlafaxine Chemical compound 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- WIQRCHMSJFFONW-UHFFFAOYSA-N norfluoxetine Chemical compound C=1C=CC=CC=1C(CCN)OC1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/062—Preparation extracting sample from raw material
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811523318.2A CN111323527B (zh) | 2018-12-13 | 2018-12-13 | 一种用复合二维液相色谱同时测定多种精神药物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811523318.2A CN111323527B (zh) | 2018-12-13 | 2018-12-13 | 一种用复合二维液相色谱同时测定多种精神药物的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111323527A true CN111323527A (zh) | 2020-06-23 |
CN111323527B CN111323527B (zh) | 2022-12-02 |
Family
ID=71168370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811523318.2A Active CN111323527B (zh) | 2018-12-13 | 2018-12-13 | 一种用复合二维液相色谱同时测定多种精神药物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111323527B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114113349A (zh) * | 2020-08-26 | 2022-03-01 | 湖南农业大学 | 一种基于二维液相色谱-紫外衍生法同时测定生物基质中5种氨基酸类神经递质的方法 |
CN115728415A (zh) * | 2022-11-11 | 2023-03-03 | 内蒙古帕默康创医疗仪器有限公司 | 舒必利血药浓度的定量分析方法 |
CN117607317A (zh) * | 2023-12-01 | 2024-02-27 | 上海市民政第三精神卫生中心 | 一种测定人血浆中抑郁症药物的方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1143634A (zh) * | 1996-06-25 | 1997-02-26 | 厦门大学 | 对映体纯3-氨基-1,2-二取代吡咯烷的立体选择性合成方法 |
CN101666786A (zh) * | 2008-09-02 | 2010-03-10 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种分离柱与喷针一体化的毛细管柱装填和塞子制作方法 |
EP2774991A1 (en) * | 2013-03-06 | 2014-09-10 | Life Science Inkubator Betriebs GmbH & Co. KG | Drug delivery system for use in the treatment or diagnosis of neurological disorders |
CN105092739A (zh) * | 2015-09-18 | 2015-11-25 | 江南大学 | 一种固相萃取-液相色谱联用法测定黄酒中7种有机酸的方法 |
CN106546671A (zh) * | 2016-10-17 | 2017-03-29 | 浙江省食品药品检验研究院 | 基于三柱二维液质联用法测定肉制品中残留磺胺类药物的方法 |
CN108982714A (zh) * | 2018-06-06 | 2018-12-11 | 上海市精神卫生中心(上海市心理咨询培训中心) | 一种简便高效检测人血浆中文拉法辛及其活性代谢物o-去甲文拉法辛浓度的方法 |
-
2018
- 2018-12-13 CN CN201811523318.2A patent/CN111323527B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1143634A (zh) * | 1996-06-25 | 1997-02-26 | 厦门大学 | 对映体纯3-氨基-1,2-二取代吡咯烷的立体选择性合成方法 |
CN101666786A (zh) * | 2008-09-02 | 2010-03-10 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种分离柱与喷针一体化的毛细管柱装填和塞子制作方法 |
EP2774991A1 (en) * | 2013-03-06 | 2014-09-10 | Life Science Inkubator Betriebs GmbH & Co. KG | Drug delivery system for use in the treatment or diagnosis of neurological disorders |
CN105092739A (zh) * | 2015-09-18 | 2015-11-25 | 江南大学 | 一种固相萃取-液相色谱联用法测定黄酒中7种有机酸的方法 |
CN106546671A (zh) * | 2016-10-17 | 2017-03-29 | 浙江省食品药品检验研究院 | 基于三柱二维液质联用法测定肉制品中残留磺胺类药物的方法 |
CN108982714A (zh) * | 2018-06-06 | 2018-12-11 | 上海市精神卫生中心(上海市心理咨询培训中心) | 一种简便高效检测人血浆中文拉法辛及其活性代谢物o-去甲文拉法辛浓度的方法 |
Non-Patent Citations (9)
Title |
---|
CHRISTINE FRAHNERT 等: "Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring", 《JOURNAL OF CHROMATOGRAPHY B》, vol. 794, 31 December 2003 (2003-12-31), pages 35 - 47, XP004441226, DOI: 10.1016/S1570-0232(03)00393-3 * |
H. KIRCHHERR 等: "Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: A multi-level, single-sample approach", 《JOURNAL OF CHROMATOGRAPHY B》, vol. 843, 31 December 2006 (2006-12-31), pages 100 - 113, XP025122512, DOI: 10.1016/j.jchromb.2006.05.031 * |
LUDMILA MUT 等: "Toxicological screening of human plasma by on‐line SPE‐HPLC‐DAD: identification and quantification of basic drugs and metabolites", 《BIOMEDICAL CHROMATOGRAPHY》, vol. 29, 17 November 2014 (2014-11-17), pages 935 - 952 * |
倪晓佳等: "基于液相色谱-二级质谱联用技术精神科药物中毒筛查平台的构建与临床应用", 《中国医院药学杂志》, no. 17, 30 September 2017 (2017-09-30), pages 1671 - 1674 * |
冯碧敏 等: "高效液相色谱法测定盐酸文拉法辛缓释片的主药含量", 《中国医院用药评价与分析》, vol. 12, no. 5, 31 December 2012 (2012-12-31), pages 440 - 442 * |
刘丽娜等: "混合型硅胶基质高效液相色谱填料的制备与表征", 《北京化工大学学报(自然科学版)》, no. 04, 20 July 2013 (2013-07-20), pages 80 - 84 * |
张宏久 等: "人血清中舒必利的高效液相色谱测定与临床应用", 《临床药学》, vol. 14, no. 12, 31 December 2005 (2005-12-31), pages 84 - 85 * |
肖俊辉 等: "二维高效液相色谱结合拦截技术测定舒巴坦血药浓度", 《中南药学》, vol. 15, no. 5, 31 May 2017 (2017-05-31), pages 591 - 594 * |
陈颖 等: "用HPLC法同时测定人血清中舒必利、硫必利和氨磺必利的浓度", 《药学服务与研究》, vol. 18, no. 5, 31 October 2018 (2018-10-31), pages 356 - 359 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114113349A (zh) * | 2020-08-26 | 2022-03-01 | 湖南农业大学 | 一种基于二维液相色谱-紫外衍生法同时测定生物基质中5种氨基酸类神经递质的方法 |
CN114113349B (zh) * | 2020-08-26 | 2024-01-23 | 湖南农业大学 | 一种基于二维液相色谱-紫外衍生法同时测定生物基质中5种氨基酸类神经递质的方法 |
CN115728415A (zh) * | 2022-11-11 | 2023-03-03 | 内蒙古帕默康创医疗仪器有限公司 | 舒必利血药浓度的定量分析方法 |
CN117607317A (zh) * | 2023-12-01 | 2024-02-27 | 上海市民政第三精神卫生中心 | 一种测定人血浆中抑郁症药物的方法 |
CN117607317B (zh) * | 2023-12-01 | 2024-04-26 | 上海市民政第三精神卫生中心 | 一种测定人血浆中抑郁症药物的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111323527B (zh) | 2022-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104614479B (zh) | 一种食品中维生素的检测方法 | |
CN111323527B (zh) | 一种用复合二维液相色谱同时测定多种精神药物的方法 | |
CN101430307B (zh) | 一种同时分析氨基酸和有机酸代谢物谱的方法 | |
CN103487518B (zh) | 注射用盐酸克林霉素杂质的检测方法及含量测定方法 | |
CN110988193B (zh) | 一种检测水产品中晚期糖基化终末产物的方法 | |
CN102539558A (zh) | 一种卷烟主流烟气中硫化氢的测定方法 | |
CN106645477B (zh) | 一种检测氟苯尼考胺残留的方法及应用 | |
CN106033079B (zh) | 甲磺酸达比加群酯起始物料f中有关物质咪唑的检测方法 | |
CN209416990U (zh) | 一种复合色谱柱以及一种二维液相色谱系统 | |
CN111323492A (zh) | 一种复合色谱柱以及一种二维液相色谱系统 | |
CN104634911B (zh) | 一种喘可治注射液4种黄酮类有效成分检测方法 | |
CN115902009A (zh) | 细胞培养液中葡萄糖含量的测定方法 | |
CN102636582B (zh) | 测定三氮脒颗粒中三氮脒和安替比林含量的方法 | |
CN115308335A (zh) | 阿立哌唑血药浓度检测方法 | |
CN111198235B (zh) | 一种血浆中异橙黄酮含量的检测方法 | |
CN113866305A (zh) | 一种基于液质联用技术快速精准分析茶鲜叶中茶氨酸的方法 | |
CN110208419B (zh) | 一种用于检测比伐卢定中杂质的方法 | |
CN100383520C (zh) | 一种测定人血浆中霉酚酸及其代谢物的方法 | |
CN109061009B (zh) | 一种发酵液中衣康酸含量的测定方法 | |
CN108008035B (zh) | 3-乙氧基-4-甲氧基苯甲醛纯度的检测方法 | |
CN105784905A (zh) | 宠物食品中赭曲霉毒素b的液相色谱-串联质谱检测方法 | |
CN112198236B (zh) | 一种瓜氨酸原料中瓜氨酸含量的检测方法 | |
CN110824038A (zh) | 一种2,3,4,6-四-o-三甲基硅基-d-葡糖酸内酯的液相色谱分析方法 | |
CN118150728B (zh) | 一种复方脑蛋白水解物片中维生素b1降解杂质的分析方法 | |
CN115290766A (zh) | 一种准确快速测定抗体药物中2-脱氧-2-氟-l-岩藻糖含量的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for simultaneous determination of multiple psychotropic drugs using composite two-dimensional liquid chromatography Effective date of registration: 20230720 Granted publication date: 20221202 Pledgee: China Merchants Bank Co.,Ltd. Changsha Branch Pledgor: HUNAN DEMETER INSTRUMENT CO.,LTD. Registration number: Y2023980049129 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20221202 Pledgee: China Merchants Bank Co.,Ltd. Changsha Branch Pledgor: HUNAN DEMETER INSTRUMENT CO.,LTD. Registration number: Y2023980049129 |